CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 9, 2003, Pages 928-932

  Plummer, Sarah J ^a   Conti, David V ^b,c   Paris, Pamela L ^a,d   Curran, Anthony P ^a   Casey, Graham ^a   Witte, John S ^b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

AGE FACTORS; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; OHIO; PROSTATIC NEOPLASMS; RISK FACTORS; SIBLINGS; VARIATION (GENETICS);

EID: 0141495183     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer Statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Pienta, K. J., and Esper, P. S. Risk factors for prostate cancer. Ann. Intem. Med., 118: 793-803, 1993.
3. Coughlin, S. S., and Hall, I. J. A review of genetic polymorphisms and prostate cancer risk. Ann. Epidemiol., 12: 182-196, 2002.
4. Nwosu, V., Carpten, J., Trent, J. M., and Sheridan, R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum. Mol. Genet., 10: 2313-2318, 2001.
5. Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A., and El-Sankary, W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica, 32: 165-206, 2002.
6. Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., Bishop, C., Koebe, H-G., Brinkmann, U., Klenk, H-P., Kleine, K., Meyer, U. A., and Wojnowski, L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11: 111-121, 2001.
7. Ozdemir, V., Kalowa, W., Tang, B. K., Paterson, A. D., Walker, S. E., Endrenyi, L., and Kashuba, A. D. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10: 373-388, 2000.
8. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst., 90: 1225-1229, 1998.
9. Paris, P. L., Kupelian, P. A., Hall, J. M., Williams, T. L., Levin, H., Klein, E. A., Casey, G., and Witte, J. S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomark. Prev., 8: 901-905, 1999.
10. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B., and Ingelman-Sundberg, M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun., 259: 201-205, 1999.
11. Wandel, C., Witte, J. S., Hall, J. M., Stein, C. M., Wood. A. J. J., and Wilkinson, G. R. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Pharmacogenetics Genomics, 68: 82-91, 2000.
12. Ando, Y., Tateishi, T., Sekido, Y., Yamamoto. T., Satoh, T., Hasegawa, Y., Kobayahsi, S., Katsumata, Y., Shimokata, K., and Saito, H. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst., 91: 1587-1588, 1999.
13. Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., Warner, M., and Hall, J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther., 66: 288-294, 1999.
14. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38: 207-213, 1990.
15. Schuetz, J. D., Beach, D. L., and Guzelian, P, S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4: 11-20, 1994.
16. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brockmolle, J., Halper, J. R., Zanger, U. M., and Wojnowski, L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11: 773-779, 2001.
17. Kuehl, P., Zhang, J., Lin. Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S., and Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391, 2001.
18. Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhange, J., Lamba, J., Schuetz, E. G., and Thummel, K. E. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol., 62: 162-172, 2002.
19. Finnstrom, N., Bjelfman, C., Soderstrom, T. G., Smith, G., Egevad, L., Norlen, B. J., Wolf, C. R., and Rane, A. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Investig., 10: 880-886. 2001.
20. Wojnowski, L., Hustert, E., Klein, K., Goldhammer, M., Haberl, M., Kirchheiner, J., Koch, I., Klattig, J., Zanger, U., and Brockmoller, J. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst., 94: 630-631, 2002.
21. Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., and Oscarson, M. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43, Biochem. Biophys. Res. Commun., 281: 1349-1355, 2001.
22. Lubin, J. H., and Hartge, P. Excluding controls: misapplications in case-control studies. Am. J. Epidemiol., 120: 791-793, 1984.
23. Poole, C. Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am. J. Epidemiol., 150: 547-551, 1999.
24. Witte, J. S., Gauderman, W. J., and Thomas, D. C. Asymptomatic bias and efficiency in case-control studies of candidate genes and gene-environmental interactions: basic family designs. Am. J. Epidemiol., 149: 693-705, 1999.
25. Little, S. Amplification-Refractory Mutation System (ARMS) Analysis of Point Mutations. In: N. C. Dracopoli, J. L. Haines, B. R. Koff, C. C. Morton, C. E. Seidman, J. G. Seidman, and D. R. Smith (eds.), Current Protocols in Human Genetics 2, pp. 9.8.1-9.8.12. New York, New York: John Wiley & Sons, Inc., 2000.
26. Stephens, M., Smith, N. J., and Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68: 978-989, 2001.
27. Sobin, L. H., and Wittekind, C. TNM Classification of Malignant Tumors. New York: Wiley-Liss. 1997.
28. Kittles, R. A., Chen, W., Panguluri, R. K., Ahaghotu, C., Jackson, A., Adebamowo, C. A., Griffin, R., Williams, T., Ukoli, F., Adams-Campbell, L., Kwagyan, J., Isaacs, W., Freeman, V., and Dunston, G. M. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet., 110: 553-560, 2002.
29. Burk, O., Tegude, H., I., K., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., Zanger, U. M., Eichelbaum, M., and Wojnowski, L. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem., 277: 24280-24288, 2002.
30. Ohmori, S., Nakasa, H., Asanome, K., Kurose, Y., Ishii, I., Hosokawa, M., and Kitada. M. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochem. Biophys. Acta, 1380: 297-304, 1998.
31. Gillam, E. M. J., Guo, Z., Ueng, Y. F., Yamazaki, H., Cock, I., Reilly, P. E., Hooper, W. D., and Guengerich, F. P. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys., 318: 374-384, 1995.